High-dose continuous infusion β-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in immunocompromised patients

Annals of Pharmacotherapy

Volumn 44, Issue 5, 2010, Pages 929-935

  Moriyama, Brad ^a   Henning, Stacey A ^a   Childs, Richard ^b   Holland, Steven M ^c   Anderson, Victoria L ^c   Morris, John C ^d   Wilson, Wyndham H ^d   Drusano, George L ^e   Walsh, Thomas J ^d  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

lactam antibiotics; Continuous infusion; Immunocompromised; Pseudomonas aeruginosa; Resistance

Indexed keywords

AZITHROMYCIN; AZTREONAM; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IMIPENEM; LEVOFLOXACIN; MEROPENEM; POLYMYXIN B; PREDNISONE; TOBRAMYCIN; VANCOMYCIN; VINCRISTINE;

ADOLESCENT; ADULT; ANAMNESIS; ANTIBIOTIC RESISTANCE; APLASTIC ANEMIA; ARTICLE; BACTEREMIA; CANCER CHEMOTHERAPY; CASE REPORT; CONTINUOUS INFUSION; CUTANEOUS T CELL LYMPHOMA; DRUG DOSE REDUCTION; DRUG MEGADOSE; FACIAL FASCICULATION; FASCICULATION; FEMALE; FEVER; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPROMISED PATIENT; LEUKOCYTE ADHESION DEFICIENCY; LOADING DRUG DOSE; MALE; MINIMUM INHIBITORY CONCENTRATION; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; SINUSITIS; T CELL LEUKEMIA; TREATMENT OUTCOME; VIRUS PNEUMONIA; WOUND INFECTION;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; INFUSIONS, INTRAVENOUS; MALE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TREATMENT OUTCOME;

EID: 77951524567     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M717     Document Type: Article

References (32)

1. National Nosocomial Infections Surveillance (NNIS) System report. Data summary from January 1990-May 1999, issued June 1999. Am J Infect Control 1999;27:520-532
2. Streit JM, Jones RN, Sader HS, Fritsche TR. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Int J Antimicrob Agents 2004;24:111-118
3. Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005;49:1306-1311
4. Hakki M, Limaye AP, Kim HW, Kirby KA, Corey L, Boeckh M. Invasive Pseudomonas aeruginosa infections: high rate of recurrence and mortality after hematopoietic cell transplantation. Bone Marrow Transplant 2007;39:687-693
5. Crouch Brewer S, Wunderink RG, Jones CB, Leeper KV Jr. Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest 1996;109:1019-1029
6. Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, Bartlett JG. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006;42:657-668 (Pubitemid 43271379)
7. O'Neill AJ. New antibacterial agents for treating infections caused by multi-drug resistant gram-negative bacteria. Expert Opin Investig Drugs 2008;17:297-302.
8. Johansen HK, Moskowitz SM, Ciofu O, Pressler T, Hoiby N. Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients. J Cyst Fibros 2008;7:391-397
9. Lodise TP, Lomaestro BM, Drusano GL; Society of Infectious Diseases Pharmacists. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2006;26:1320-1332
10. DeRyke CA, Lee SY, Kuti JL, Nicolau DP. Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistance. Drugs 2006;66:1-14.
11. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-10.
12. Bauer LA. Applied clinical pharmacokinetics. New York: McGraw-Hill, 2001:39-41.
13. Mouton JW, Vinks AA. Is continuous infusion of beta-lactam antibiotics worthwhile? - efficacy and pharmacokinetic considerations. J Antimicrob Chemother 1996;38:5-15.
14. Moriyama B, Henning SA, Neuhauser MM, Danner RL, Walsh TJ. Continuous-infusion β-lactam antibiotics during continuous venovenous hemofiltration for the treatment of resistant gram-negative bacteria. Ann Pharmacother 2009;43:1324-1337 DOI 10.1345/aph.1L638
15. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
16. Daenen S, de Vries-Hospers H. Cure of Pseudomonas aeruginosa infection in neutropenic patients by continuous infusion of ceftazidime (letter). Lancet 1988;1:937.
17. Vinks AA, Brimicombe RW, Heijerman HG, Bakker W. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics. J Antimicrob Chemother 1997;40:125-133 (Pubitemid 27341645)
18. Bosso JA, Bonapace CR, Flume PA, White RL. A pilot study of the efficacy of constant-infusion ceftazidime in the treatment of endobronchial infections in adults with cystic fibrosis. Pharmacotherapy 1999;19:620-626
19. Rappaz I, Decosterd LA, Bille J, Pilet M, Bélaz N, Roulet M. Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children. Eur J Pediatr 2000;159:919-925
20. Kuzemko J, Crawford C. Continuous infusion of ceftazidime in cystic fibrosis (letter). Lancet 1989;2:385. (Pubitemid 19189086)
21. Hubert D, Le Roux E, Lavrut T, et al. Continuous versus intermittent infusions of ceftazidime for exacerbation of cystic fibrosis. Antimicrob Agents Chemother 2009;53:3650-3656
22. Domenig C, Traunmüller F, Kozek S, et al. Continuous beta-lactam antibiotic therapy in a double-lung transplanted patient with a multidrug-resistant Pseudomonas aeruginosa infection. Transplantation 2001;71:744-745
23. Hayes D Jr, Kanga JF, Anstead MI, Kuhn RJ. Novel approach to the eradication of Pseudomonas aeruginosa in an infant with CF after outpatient treatment failure. Pediatr Pulmonol 2008;43:511-513
24. Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-751 (Pubitemid 34194843)
25. Mouton JW, den Hollander JG. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1994;38:931-936
26. Tessier PR, Nicolau DP, Onyeji CO, Nightingale CH. Pharmacodynamics of intermittent- and continuous-infusion cefepime alone and in combination with once-daily tobramycin against Pseudomonas aeruginosa in an in vitro infection model. Chemotherapy 1999;45:284-295
27. Robaux MA, Dube L, Caillon J, et al. In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model. J Antimicrob Chemother 2001;47:617-622
28. Navas D, Caillon J, Gras-Le Guen C, et al. Comparison of in vivo intrinsic activity of cefepime and imipenem in a Pseudomonas aeruginosa rabbit endocarditis model: effect of combination with tobramycin simulating human serum pharmacokinetics. J Antimicrob Chemother 2004;54:767-771
29. Piccoli L, Larosa M, Marchetti F. Time-kill curves as a tool for targeting ceftazidime serum concentration during continuous infusion. J Antimicrob Chemother 2003;52:1047-1048 (Pubitemid 38008436)
30. Alou L, Aguilar L, Sevillano D, et al. Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model. J Antimicrob Chemother 2005;55:209-213 (Pubitemid 40694558)
31. Chow KM, Hui AC, Szeto CC. Neurotoxicity induced by beta-lactam antibiotics: from bench to bedside. Eur J Clin Microbiol Infect Dis 2005;24:649-653 (Pubitemid 41670564)
32. Schliamser SE, Cars O, Norrby SR. Neurotoxicity of beta-lactam antibiotics: predisposing factors and pathogenesis. J Antimicrob Chemother 1991;27:405-425